de JP Morgan Chase Novartis NVS Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 357 M | Comprar |
2,264,447
+459,771
| +25% | +USD 68.9 M | 0.02% | 554 |
|
|
2026
Q1 | USD 271 M | Comprar |
1,804,676
+1,212,024
| +205% | +USD 186 M | 0.02% | 579 |
|
|
2025
Q4 | USD 81.7 M | Comprar |
592,652
+55,109
| +10% | +USD 7.22 M | 0.01% | 1042 |
|
|
2025
Q3 | USD 68.9 M | Comprar |
537,543
+82,226
| +18% | +USD 10 M | ﹤0.01% | 1203 |
|
|
2025
Q2 | USD 55.1 M | Vender |
455,317
-88,021
| -16% | -USD 9.9 M | ﹤0.01% | 1277 |
|
|
2025
Q1 | USD 60.6 M | Comprar |
543,338
+120,196
| +28% | +USD 12.8 M | ﹤0.01% | 1206 |
|
|
2024
Q4 | USD 41.2 M | Comprar |
423,142
+111,066
| +36% | +USD 11.8 M | ﹤0.01% | 1448 |
|
|
2024
Q3 | USD 35.9 M | Vender |
312,076
-5,738
| -2% | -USD 651 k | ﹤0.01% | 1553 |
|
|
2024
Q2 | USD 33.8 M | Vender |
317,814
-87,017
| -21% | -USD 8.73 M | ﹤0.01% | 1473 |
|
|
2024
Q1 | USD 39.2 M | Comprar |
404,831
+54,370
| +16% | +USD 5.57 M | ﹤0.01% | 1426 |
|
|
2023
Q4 | USD 35.4 M | Vender |
350,461
-9,438
| -3% | -USD 911 k | ﹤0.01% | 1425 |
|
|
2023
Q3 | USD 36.7 M | Vender |
359,899
-27,138
| -7% | -USD 2.75 M | ﹤0.01% | 1269 |
|
|
2023
Q2 | USD 39.1 M | Vender |
387,037
-24,038
| -6% | -USD 2.4 M | ﹤0.01% | 1231 |
|
|
2023
Q1 | USD 37.8 M | Vender |
411,075
-24,656
| -6% | -USD 2.15 M | ﹤0.01% | 1235 |
|
|
2022
Q4 | USD 39.5 M | Vender |
435,731
-111,014
| -20% | -USD 9.35 M | 0.01% | 1235 |
|
|
2022
Q3 | USD 41.6 M | Vender |
546,745
-116,250
| -18% | -USD 9.6 M | 0.01% | 1139 |
|
|
2022
Q2 | USD 56 M | Comprar |
662,995
+444,401
| +203% | +USD 39 M | 0.01% | 987 |
|
|
2022
Q1 | USD 19.2 M | Vender |
218,594
-49,776
| -19% | -USD 4.31 M | ﹤0.01% | 1793 |
|
|
2021
Q4 | USD 23.5 M | Vender |
268,370
-38,165
| -12% | -USD 3.17 M | ﹤0.01% | 1691 |
|
|
2021
Q3 | USD 25.1 M | Comprar |
306,535
+4,378
| +1% | +USD 394 k | ﹤0.01% | 1586 |
|
|
2021
Q2 | USD 27.6 M | Comprar |
302,157
+16,007
| +6% | +USD 1.43 M | ﹤0.01% | 1578 |
|
|
2021
Q1 | USD 24.5 M | Vender |
286,150
-96,641
| -25% | -USD 8.67 M | ﹤0.01% | 1580 |
|
|
2020
Q4 | USD 36.1 M | Comprar |
382,791
+24,827
| +7% | +USD 2.17 M | 0.01% | 1242 |
|
|
2020
Q3 | USD 31.2 M | Comprar |
357,964
+11,551
| +3% | +USD 1 M | 0.01% | 1216 |
|
|
2020
Q2 | USD 30.3 M | Vender |
346,413
-83,295
| -19% | -USD 7.19 M | 0.01% | 1121 |
|
|
2020
Q1 | USD 35.4 M | Comprar |
429,708
+17,098
| +4% | +USD 1.53 M | 0.01% | 948 |
|
|
2019
Q4 | USD 39.1 M | Vender |
412,610
-221,899
| -35% | -USD 19.9 M | 0.01% | 1101 |
|
|
2019
Q3 | USD 55.1 M | Comprar |
634,509
+213,328
| +51% | +USD 19.2 M | 0.01% | 900 |
|
|
2019
Q2 | USD 38.3 M | Vender |
421,181
-109,595
| -21% | -USD 9.28 M | 0.01% | 1123 |
|
|
2019
Q1 | USD 45.7 M | Vender |
530,776
-584,040
| -52% | -USD 46.9 M | 0.01% | 1008 |
|
|
2018
Q4 | USD 85.7 M | Comprar |
1,114,816
+489,263
| +78% | +USD 38.1 M | 0.02% | 677 |
|
|
2018
Q3 | USD 48.3 M | Vender |
625,553
-157,012
| -20% | -USD 11.6 M | 0.01% | 1036 |
|
|
2018
Q2 | USD 53 M | Comprar |
782,565
+5,224
| +0.7% | +USD 360 k | 0.01% | 939 |
|
|
2018
Q1 | USD 56.3 M | Comprar |
777,341
+43,007
| +6% | +USD 3.27 M | 0.01% | 875 |
|
|
2017
Q4 | USD 55.2 M | Comprar |
734,334
+16,737
| +2% | +USD 1.26 M | 0.01% | 925 |
|
|
2017
Q3 | USD 54.5 M | Comprar |
717,597
+34,406
| +5% | +USD 2.6 M | 0.01% | 882 |
|
|
2017
Q2 | USD 51.1 M | Comprar |
683,191
+87,384
| +15% | +USD 6.19 M | 0.01% | 900 |
|
|
2017
Q1 | USD 39.6 M | Vender |
595,807
-269,413
| -31% | -USD 18 M | 0.01% | 1054 |
|
|
2016
Q4 | USD 56.5 M | Comprar |
865,220
+346,653
| +67% | +USD 22.5 M | 0.01% | 834 |
|
|
2016
Q3 | USD 36.7 M | Vender |
518,567
-996,024
| -66% | -USD 72.6 M | 0.01% | 981 |
|
|
2016
Q2 | USD 112 M | Vender |
1,514,591
-143,846
| -9% | -USD 9.9 M | 0.03% | 529 |
|
|
2016
Q1 | USD 108 M | Comprar |
1,658,437
+143,110
| +9% | +USD 9.7 M | 0.03% | 526 |
|
|
2015
Q4 | USD 117 M | Vender |
1,515,327
-300,811
| -17% | -USD 23.9 M | 0.03% | 515 |
|
|
2015
Q3 | USD 150 M | Vender |
1,816,138
-9,601
| -0.5% | -USD 854 k | 0.04% | 435 |
|
|
2015
Q2 | USD 161 M | Vender |
1,825,739
-24,325
| -1% | -USD 2.23 M | 0.04% | 454 |
|
|
2015
Q1 | USD 163 M | Vender |
1,850,064
-2,030
| -0.1% | -USD 180 k | 0.04% | 482 |
|
|
2014
Q4 | USD 154 M | Vender |
1,852,094
-353,384
| -16% | -USD 29.3 M | 0.04% | 500 |
|
|
2014
Q3 | USD 186 M | Comprar |
2,205,478
+105,074
| +5% | +USD 8.5 M | 0.04% | 423 |
|
|
2014
Q2 | USD 170 M | Comprar |
2,100,404
+19,755
| +0.9% | +USD 1.55 M | 0.04% | 425 |
|
|
2014
Q1 | USD 159 M | Comprar |
2,080,649
+197,729
| +11% | +USD 14.4 M | 0.04% | 424 |
|
|
2013
Q4 | USD 136 M | Vender |
1,882,920
-379,134
| -17% | -USD 26.4 M | 0.04% | 443 |
|
|
2013
Q3 | USD 155 M | Comprar |
2,262,054
+680,923
| +43% | +USD 45.1 M | 0.05% | 401 |
|
|
2013
Q2 | USD 100 M | Comprar |
+1,581,131
| Nuevas | +USD 103 M | 0.03% | 507 |
|
Otros fondos que tienen NVS en su cartera
Posición de JP Morgan Chase en NVS: resumen de T2 2026
JP Morgan Chase aumentó su participación en Novartis (NVS) en 25% durante T2 2026, al comprar aproximadamente USD 68.9 M y elevar la posición a 2,264,447 acciones con un valor de USD 357 M. La posición representa 0.02% de la cartera y ocupa el puesto #554.
JP Morgan Chase reportó por primera vez una posición en NVS en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 1,631 fondos que sigue Wall St. Rank mantienen una posición en NVS.
- Al cierre de T2 2026, JP Morgan Chase tenía 2,264,447 acciones de Novartis con un valor de USD 357 M.
- JP Morgan Chase compró 459,771 acciones de Novartis en T2 2026, por un monto estimado de USD 68.9 M.
- Novartis representó 0.02% de la cartera de JP Morgan Chase en T2 2026 y fue su posición número 554.
- JP Morgan Chase reportó por primera vez una posición en Novartis en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 1,631 fondos que sigue Wall St. Rank tenían Novartis en cartera.
Según el Informe 13F de JP Morgan Chase correspondiente a T2 2026, presentado el 12 ago 2026.